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Alveolar soft part sarcoma is an extremely rare soft tissue sarcoma with poor prognosis. It is characterized by the
unbalanced recurrent chromosomal translocation der(17)t(X;17)(p11;q25), resulting in the generation of anASPL-TFE3
fusion gene. ASPL-TFE3 oncoprotein functions as an aberrant transcriptional factor and is considered to play a crucial
role in the tumorigenesis of alveolar soft part sarcoma. However, the underlying molecular mechanisms are poorly
understood. In this study, we identified p21 (p21WAF1/CIP1) as a direct transcriptional target of ASPL-TFE3. Ectopic
ASPL-TFE3 expression in 293 cells resulted in cell cycle arrest and significant increases in protein andmRNA levels of
p21. ASPL-TFE3 activated p21 expression in a p53-independentmanner throughdirect transcriptional interactionswith
the p21 promoter region. When ASPL-TFE3 was expressed in human bonemarrow–derived mesenchymal stem cells
in a tetracycline-inducible manner, we observed the up-regulation of p21 expression and the induction of senescence-
associated β-galactosidase activity. Suppression of p21 significantly decreased the induction of ASPL-TFE3-mediated
cellular senescence. Furthermore, ASPL-TFE3 expression in mesenchymal stem cells resulted in a significant up-
regulation of proinflammatory cytokines associated with senescence-associated secretory phenotype (SASP). These
results show that ASPL-TFE3 regulates cell cycle progression and induces cellular senescence by up-regulating p21
expression. In addition, our data suggest a potential mechanism bywhich ASPL-TFE3-induced senescencemay play a
role in tumorigenesis by inducing SASP, which could promote the protumorigenic microenvironment.
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Alveolar soft part sarcoma (ASPS) is an extremely rare sarcoma with
unclear origins, comprising 0.5% to 1.0% of all soft tissue sarcomas [1].
Although ASPS typically presents as a slow-growing tumor, its overall
survival rate is poor because of chemoresistance and the high incidence
of pulmonary and brain metastases during the early stages of this disease
[2–4]. Moreover, almost all cases of ASPS have the unbalanced
recurrent chromosomal translocation der(17)t(X;17)(p11;q25), which
results in generation of the ASPL-TFE3 (also known as
ASPSCR1-TFE3) fusion gene [5]. Because the ASPL gene is joined
in frame with either the third (type 1) or fourth (type 2) exon of TFE3,
two types of fusion transcripts have been identified [5].
TFE3 belongs to themicrophthalmia transcription factor-transcription
factor E (MiTF-TFE) basic helix–loop-helix leucine zipper transcription
factor family, which binds to the E-box DNA consensus sequence
CANNTG [6,7]. In a subset of renal cell carcinomas with the
translocation Xp11.2, TFE3 fuses with PRCC, CLTC, PSF, NonO,PARP14, LUC7L3, KHSRP, and DVL2, resulting in the expression of
PRCC-TFE3, CLTC-TFE3, PSF-TFE3, NonO-TFE3,
PARP14-TFE3, LUC7L3-TFE3, KHSRP-TFE3, and DVL2-TFE3
fusion oncogenes, respectively [8–14]. In addition, ASPL-TFE3-positive
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have only been partially characterized, but the mouse homolog TUG is a
tethering protein that forces the retention of GLUT4-containing vesicles
in the cytoplasm in the absence of insulin [16].
The ASPL-TFE3 fusion gene retains the DNA binding and
activation domain of TFE3, whereas the N-terminal region of TFE3
is replaced with ASPL sequences [5]. The ASPL-TFE3 oncoprotein is
believed to play crucial roles in the progression of ASPS. ASPL-TFE3
functions as an aberrant transcriptional factor and induces the
inappropriate up-regulation of various molecules that contribute to
the pathogenesis and progression of ASPS [17]. Indeed, several TFE3
fusion oncoproteins, including ASPL-TFE3, up-regulate the Met
receptor tyrosine kinase gene and induce oncogenic phenotypes such
as uncontrolled cell proliferation, invasion, and metastasis [18].
However, the molecular roles of ASPL-TFE3 are poorly understood.
Deregulated cell proliferation is critical to tumor formation and
progression. Because TFE3 plays roles in the regulation of cell growth
[19–21], we hypothesized that ASPL-TFE3 may affect the
proliferation of tumor cells by inducing inappropriate expression of
cell cycle regulatory proteins. Therefore, we investigated the effects of
ASPL-TFE3 on the cell cycle machinery. In this paper, we report that
ASPL-TFE3 affected the cell cycle machinery by the direct
transcriptional up-regulation of p21. In addition, we reveal that the
expression of ASPL-TFE3 in mesenchymal stem cells (MSCs)
induced p21-mediated cellular senescence and increased the mRNA
level of proinflammatory cytokines.
Materials and Methods
Cells
HeLa human cervical carcinoma cells, 293 human embryonic
kidney cells, KATO III human gastric cancer cells, and UE7T-13
human bone marrow-derived MSCs, which were immortalized using
retroviruses expressing human papillomavirus protein E7 and human
telomerase catalytic subunit (hTERT) [22], were obtained from
Health Science Research Resource Bank (Osaka, Japan). Cells were
maintained under 5% CO2 at 37°C in Dulbecco's modified Eagle's
medium (Nissui, Tokyo, Japan) containing 10% fetal bovine serum.
Tissue Sample
Frozen tissue was obtained from a patient who underwent surgical
treatment for ASPS. Written informed consent was obtained for
tissue to be used in research. This study was approved by the Ethics
Committee of Tottori University.
Cloning and Reverse Transcription Polymerase Chain Reaction
Total RNA was isolated from frozen tissue of ASPS patient using
ISOGEN (Nippon GENE, Tokyo, Japan) according to the
manufacturer's instructions and a cDNA clone encoding human
ASPL-TFE3 was subsequently amplified by reverse transcription
polymerase chain reaction (RT-PCR) using a Takara PrimeScript
High Fidelity RT-PCR kit (Takara, Otsu, Japan) with the following
primers: forward, 5′-AAGCTTCACCATGGCGGCCCCGG
CAGGC-3′ (including HindIII site and Kozak sequence), and
reverse, 5′-TCACTTGTCGTCATCGTCTTTGTAGTCGGA
CTCCTCTTCCATGCT-3′ (including FLAG epitope tag sequence
and STOP codon). Amplified fragments were inserted into the
pGeMT-easy vector (Promega, Madison, WI) and DNA was
sequenced using ABI PRISM (Applied Biosystems, Foster City,
CA). DNA sequencing confirmed the identity of the type I fusiongene of ASPL-TFE3. Subsequently, ASPL-TFE3 cDNA was digested
using HindIII and NotI and inserted into the tetracycline-inducible
expression vector pcDNA4/TO (Invitrogen, Carlsbad, CA) to
produce pcDNA/TO-AT.
Transfection and Selection of Clones
For the tetracycline-regulated system (T-Rex system; Invitrogen),
293 and UE7T-13 cells were transfected with pcDNA6/TR (Invitro-
gen) and either empty pcDNA4/TO vector or pcDNA/TO-AT using
FuGENE HD transfection reagent (Roche, Mannheim, Germany),
according to the manufacturer's instructions, and these were designated
293/TR-Vec, 293/TR-AT, UE7T/TR-Vec, and UE7T/TR-AT cells,
respectively. After 24 h, cells were placed in media containing 5 μg/ml
blasticidin (Invitrogen) and 125 μg/ml Zeocin (Invitrogen), and
drug-resistant colonies were isolated. Tetracycline (1 μg/ml; Invitrogen)
was added to the growth media to induce of ASPL-TFE3 (tested by
RT-PCR and western blotting).
Cell Growth Assay
293/TR-AT and UE7T/TR-AT cells were seeded at densities of
1 × 105 and 2 × 104 cells per well, respectively, in 6 well plates.
Tetracycline or phosphate buffered saline (PBS) was added to themedia
and cells were cultured for designated times. Subsequently, cells were
trypsinized and counted using a trypan blue dye exclusion test.
Fluorescence-Activated Cell Sorting Analysis
Cells were trypsinized, harvested, and fixed at −20°C in 70%
ethanol for at least overnight. Fixed cells were stained with 1 ml of
propidium iodide (PI) solution (0.05% NP-40, 50 μg/ml propidium
iodide, and 10 μg/ml RNase A) for at least 2 h at 4°C. Stained cells
were analyzed using an EPICS ALTRA flow cytometer (Beckman
Coulter, Brea, CA).
Western Blot
Cells were suspended in lysis buffer (0.1% SDS, 40 mM Tris–HCl
(pH 7.4), 1% Nonidet P-40, 0.5% sodium deoxycholate, 150 mM
NaCl, 4 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 5 μg/ml
aprotinin, 1μg/ml leupeptin), andwere then centrifuged. Lysate samples
containing 10 to 20 μg of protein were subjected to SDS-polyacrylamide
gel electrophoresis and were then transferred to polyvinylidene difluoride
(PVDF)membranes (Millipore, Bedford,MA). PVDFmembranes were
then incubated overnight at 4°C with primary antibodies and signals
were detected using Pierce Western Blotting Substrate (Thermo
Scientific, Rockford, IL) according to the manufacturer's instructions.
Antibodies against p21, p27, p16, and cyclin dependent kinase (Cdk) 2
were obtained from BD Transduction Laboratories (Franklin Lakes,
NJ). Antibodies against FLAG and actin were purchased from Sigma (St
Louis, MO). Rb antibody was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA) and Cdk4 antibody was obtained from Epitomics
(Burlingame, CA). Phosphorylated-Rb (Ser807/811) antibody was
purchased from Cell Signaling Technology (Beverly, MA).
Plasmids
The p21 promoter (−2264 to +11 base pairs) was obtained from
the DNA Bank, RIKEN BioResource Center (Ibaraki, Japan) and was
subcloned into the pGV-B2 vector (Toyo Ink, Tokyo, Japan).
Luciferase Reporter Assay
Cells were plated on 35-mm culture dishes at a density of 2 × 105
per dish. On the next day, the cells were transfected with 0.5 μg of the
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and 0.75 μg of the pSV-β-gal vector (Promega) as a reference using
FuGENE HD reagent (Roche). After 24 h, cells were lysed and
luciferase activity was measured using a Luciferase Assay System
(Promega). The activity of firefly luciferase was normalized with the
β-galactosidase Enzyme Assay System (Promega).
Chromatin Immunoprecipitation Assays
Chromatin immunoprecipitation (ChIP) assays were performed
using ChIP-IT Express Kits (Active Motif, Carlsbad, CA) according to
the manufacturer's instructions. Briefly, cells were fixed with 1%
formaldehyde for 10 min at room temperature. After lysis, nuclei were
isolated using a Dounce homogenizer and were digested in enzymatic
shearing cocktail for 10 min. Chromatin isolates were then incubated
overnight with antibodies against FLAG (Sigma) or mouse IgG
(negative control) and protein G magnetic beads at 4°C with gentle
agitation. Subsequently, the beads were collected and washed, and
chromatin–protein complexes were eluted. Cross-linking was then
reversed by incubation for 15 min at 95°C and purified DNA was
subjected to PCR amplification using the primers 5′-TGTTTCAGG
CACAGAAAGGAGGCA-3′ and 5′-AAATCCCTGTGGTTGCAG
CAGCTT-3′ for the −1239 to −806 bp region of the p21 promoter.
Real-Time Reverse Transcription Polymerase Chain Reaction
Total RNA was isolated from cells using RNeasy mini kits (Qiagen,
Hilden, Germany), and first strand cDNA was synthesized from 500 ng
of total RNA using PrimeScript RT Reagent Kits (Takara) according to
the manufacturer's instructions. Subsequently, cDNA was subjected to
real-time PCR using Express qPCR SuperMix (Invitrogen) or GoTaq
Probe qPCR master mix (Promega). The primers used were as follows:
p21WAF/CIP1, 5′-TCACTGTCTTGTACCCTTGTGC-3′ and
5′-GGCGTTTGGAGTGGTAGAAA-3′; IL1A, 5′-AACCAGTG
CTGCTGAAGGA-3′ and 5′-TTCTTAGTGCCGTGAGTTTCC-3′;
IL1B, 5′-AAAGCTTGGTGATGTCTGGTC-3′ and 5′-GGACAT
GGAGAACACCACTTG-3 ′ ; IL6 , 5 ′ -TTCTCCACAA
GCGCCTTC-3′ and 5′-GGAATCTTCTCCTGGGGGTA-3′; IL8,
5 ′ -GAGCACTCCATAAGGCACAAA-3 ′ and 5 ′ -ATGG
TTCCTTCCGGTGGT-3′; beta-actin, 5′-GCACCCAGCACAATG
AAGA-3′ and 5′-CGATCCACACGGAGTACTTG-3′. Gene expres-
sion was normalized to that of beta-actin, and data were analyzed using
the comparative Ct method.
Senescence-Associated β-Galactosidase Staining
Cells were fixed by incubation in 2% formaldehyde/0.2%
glutaraldehyde/PBS for 5 min at room temperature and were then
stained with X-gal solution (1 mg/mL X-gal, 5 mM K3Fe[CN]6, 5
mM K4Fe[CN]6, 2 mM MgCl2 in 40 mM citric acid/Na phosphate
buffer at pH 6.0) at 37°C for 24 h.RNA Interference
Cells were seeded in 12-well plates at 5 × 104 per well and were
transfected with 150 ng siRNAs using HiPerFect reagent (Qiagen)
according to the manufacturer's instructions. The two human p21
siRNAs were purchased from Sigma Genosys (Sigma Genosys Japan,
Hokkaido, Japan) and the control siRNA was obtained from Qiagen.
The corresponding p21 siRNA sequences were GAUGGAA
CUUCGACUUUGUUU (sense-1), ACAAAGUCGAAGUUCCA
UCUU (antisense-1), CAGACCAGCAUGACAGAUUUU (sense-2),
and AAUCUGUCAUGCUGGUCUGUU (antisense-2).Statistical Analysis
The statistical significances were determined by Student's t-test
and P values b.05 were considered to be statistically significant.
Results
ASPL-TFE3 Induces Cell Cycle Arrest in 293 Cells
We established 293 cells that express ASPL-TFE3 in a
tetracycline-inducible manner, and designated them as 293/TR-AT
cells. Induction of ASPL-TFE3 expression by tetracycline addition
was confirmed by immunoblotting (Figure 1A). To determine
whether ASPL-TFE3 expression affects cell proliferation, 293/TR-AT
cells were cultured with tetracycline and their proliferation was
evaluated. As shown in Figure. 1B, the induction of ASPL-TFE3
expression in 293/TR-AT cells inhibited cell proliferation.
Fluorescence-activated cell sorting (FACS) analysis revealed that
ASPL-TFE3 expression resulted in an increase in the population of
cells in the G0/G1 phase, with a concomitant decrease in the number
of cells in the S phase (Figure 1C), suggesting that ASPL-TFE3
induces growth arrest in 293 cells.
ASPL-TFE3 Increases p21 mRNA and Protein Expression
Because cell cycle progression is regulated by complexes of cell cycle
regulatory proteins that include cyclins, Cdk, and Cdk inhibitors, we
analyzed the expression of cell cycle regulatory proteins in 293/
TR-AT cells following tetracycline treatment. The induction of
ASPL-TFE3 expression resulted in an increase in protein level of the
Cdk inhibitor p21 [23,24], whereas the expression levels of other cell
cycle regulatory proteins, including p27, p16, p53, Cdk2, and Cdk4,
showed no remarkable changes (Figure 2A). Up-regulated p21
protein expression was detectable as early as 2 h after tetracycline
treatment, in parallel with ASPL-TFE3 protein expression (Supple-
mentary Figure 1). We further investigated the phosphorylation level
of Rb, which plays a key role during the transition from G0/G1 to S
phases [25,26], and observed a decrease in its phosphorylation level
after tetracycline treatment (Figure 2A). These findings indicate that
ASPL-TFE3 expression increases p21 protein level and decreases the
phosphorylation level of Rb, resulting in growth arrest of 293 cells.
To further confirm ASPL-TFE3-induced up-regulation of p21, we
transiently transfected HeLa cells with ASPL-TFE3 and subsequently
observed an increase in p21 protein expression (Figure 2B).
Moreover, in real-time quantitative RT-PCR analyses, the induction
of ASPL-TFE3 expression in 293/TR-AT cells resulted in an
approximately 5-fold increase in p21 mRNA level (Figure 2C).
p21 is a Direct Target Gene of ASPL-TFE3
Because the ASPL-TFE3 fusion oncoprotein functions as an
aberrant transcription factor, we investigated whether ASPL-TFE3
activates the p21 gene promoter using luciferase reporter assays of the
full-length human p21 promoter. Cotransfection of the ASPL-TFE3
expression vector and the reporter vector in HeLa cells caused a
marked increase in luciferase activity compared with that following
transfection with the control empty vector (Figure 3A). Because p53
is a well-known inducer of p21 [23], we determined whether p53 is
required for activation of the p21 promoter by ASPL-TFE3, and
found that transiently expressed ASPL-TFE3 activated the p21 gene
promoter in p53-deficient (p53−/−) KATO III cells (Figure 3A). We
next investigated the binding of ASPL-TFE3 to the p21 promoter
using ChIP assays with an anti-FLAG antibody. After 24 h of
incubation with tetracycline, DNA–protein complexes were
Figure 1. Effects of ASPL-TFE3 on cell proliferation and cell cycle progression. (A) 293/TR-AT cells were cultured in the presence of
tetracycline for the indicated times and were then subjected to immunoblot analyses using the indicated antibodies. The expression
levels of ASPL-TFE3 were examined using immunoblotting with anti-FLAG antibody. (B) 293/TR-AT cells were cultured in the presence or
absence of tetracycline (+ or − Tet) for the indicated times and the cell numbers were determined. Experiments were performed twice
with triplicate determinations for each time point. Data are presented as mean ± standard deviation (SD). (C) Cell cycle distributions of
293/TR-AT cells were analyzed using FACS. 293/TR-AT cells were cultured in the presence or absence of tetracycline (+ or − Tet) for the
indicated times and were then stained with PI for FACS analyses.
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FLAG-tagged ASPL-TFE3 with the endogenous p21 promoter was
observed (Figure 3B). Collectively, these results indicate that
ASPL-TFE3 directly binds to the p21 promoter and modulates its
transcriptional activity independent of p53.
ASPL-TFE3 Induces Cellular Senescence in Human
Mesenchymal Stem Cells
Various cellular stresses, including DNA damage and oncogene
expression, cause irreversible cell cycle arrest termed premature
senescence [27]. Besides its effect on cell cycle progression, p21 has
been reported to induce cellular senescence [27,28]. Thus, we
hypothesized that ASPL-TFE3-mediated up-regulation of p21 maycontribute to the induction of cellular senescence. To investigate this
possibility, we assessed the activity of senescence-associated
β-galactosidase (SA-β-gal), a well-defined senescence biomarker
[29], in 293/TR-AT cells. However, the proportions of
SA-β-gal-positive cells were independent of ASPL-TFE3 expression
(data not shown).
Oncogene expression induces premature senescence termed
oncogene-induced senescence (OIS) in certain cell types, including
primary fibroblasts and progenitor/stem cells [27,30]. Furthermore,
recent studies have reported that the expression of sarcoma-associated
fusion oncogenes in MSCs can lead to the development of tumors
resembling sarcomas [31–34], suggesting that MSCs are a potential
model for analyzing the pathogenesis of sarcomas with specific fusion
Figure 2. ASPL-TFE3 up-regulates p21. (A) 293/TR-AT cells were cultured in the presence of tetracycline for the indicated times and were
then subjected to immunoblot analyses using the indicated antibodies. (B) HeLa cells were transiently transfected with either the vector
control or the ASPL-TFE3 expression vector and were incubated for 24 h. Cell lysates were then subjected to immunoblotting using
antibodies against FLAG, p21, and actin. (C) p21 mRNA levels were determined using real-time quantitative PCR in 293/TR-AT cells
cultured in the presence of tetracycline for 0 or 24 h. Relative p21 expression was analyzed using quantitative PCR and gene expression
data were normalized to those for beta-actin. Data are presented as fold changes in mRNA levels relative to no treatment (0 h) from three
independent experiments. Error bars show SD; ***P b .005.
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ASPL-TFE3 in UE7T-13 human bone marrow-derived MSCs
(UE7T/TR-AT cells) and confirmed the induction of ASPL-TFE3
expression by tetracycline addition using immunoblotting (Figure 4A).
As shown in Figure 4B, the addition of tetracycline resulted inFigure 3. p21 is a direct target of ASPL-TFE3. (A) Luciferase r
co-transfected into HeLa cells or p53-deficient KATO III cells with th
ASPL-TFE3. Cells were harvested 24 h after transfection and lucifera
luciferase activity relative to that in cells transfected with the con
independent experiments. ***P b .005. (B) ChIP analysis of 293/TR-A
was isolated from 293/TR-AT cells cultured in the presence of tetracy
control mouse IgG, followed by analysis by PCR amplification.
immunoprecipitation.suppression of the proliferation of UE7T/TR-AT cells. We next
examined the expression of cell cycle regulators in UE7T/TR-AT cells
and found that the induction of ASPL-TFE3 expression markedly
increased p21 protein expression, whereas the expression of p53, p16, and
p27 showed no remarkable changes (Figure 4C). To determine whethereporter plasmids containing the p21 promoter sequence were
e indicated amount of empty vector and/or expression vector for
se activity was assayed. Data are presented as the fold changes in
trol vector. Data are presented as mean ± SD of at least three
T cells using PCR primers specific for the p21 promoter. Chromatin
cline for 0 or 24 h, immunoprecipitated with anti-FLAG antibody or
Input represents the enzymatically sheared chromatin prior to
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SA-β-gal staining in UE7T/TR-AT cells following tetracycline treatment
(Figure 4D). ASPL-TFE3 expression inUE7T/TR-AT cells resulted in an
increase in the percentage of SA-β-gal-positive cells from 2% at 0 h to
20% at 24 h and 32% at 48 h after tetracycline treatment (Figure 4E).
The proportions of SA-β-gal-positive cells were increased by 46% at 4
days after tetracycline treatment, followed by a slight decrease to 35% at 8
days after tetracycline treatment (Supplementary Figure 2).
p21 is a Mediator of ASPL-TFE3-Induced Senescence
To determine whether p21 contributes to the induction of cellular
senescence by ASPL-TFE3, we suppressed p21 expression using p21
siRNAs (p21–1 and p21–2) in tetracycline-treated UE7T/TR-AT
cells (Figure 5A). UE7T/TR-AT cells were transfected with eitherFigure 4. ASPL-TFE3 induces cellular senescence in mesenchymal
tetracycline for the indicated times and were then subjected to immun
were cultured in the presence or absence of tetracycline (+ or − Te
Experiments were performed twice with triplicate determinations for
UE7T/TR-Vec and UE7T/TR-AT cells were incubated with tetracycline
the indicated antibodies. (D) SA-β-gal staining was performed in UE7T
and 48 h. (E) Proportions of SA-β-gal-positive cells in cultures of UE7
treatment for 0, 24, and 48 h. Data are presented as mean ± SD ofcontrol siRNA or p21 siRNAs, and SA-β-gal staining was performed
(Figure 5B). After 48 h of incubation with tetracycline, 31% of
control siRNA-transfected cells were positive for SA-β-gal staining,
whereas the transfection of p21 siRNAs p21–1 and p21–2 decreased the
proportions of SA-β-gal-positive cells to 16% and 17%, respectively
(Figure 5C). These findings indicate that ASPL-TFE3-induced
senescence is mediated at least in part by p21 expression.
ASPL-TFE3 Up-Regulates The Expression of
Proinflammatory Cytokines
One of the hallmarks of senescent cells is the senescence-associated
secretory phenotype (SASP), which influences the microenvironment
via the secretion of proinflammatory cytokines and growth factors
[35,36]. Senescent cells have undergone widespread changes instem cells. (A) UE7T/TR-AT cells were cultured in the presence of
oblot analyses using the indicated antibodies. (B) UE7T/TR-AT cells
t) for the indicated times and cell numbers were then determined.
each time point. Data are presented as mean ± SD. *P b .05. (C)
for 0, 24, and 48 h and were then subjected to immunoblotting with
/TR-Vec and UE7T/TR-AT cells after tetracycline treatment for 0, 24,
T/TR-Vec and UE7T/TR-AT cells were calculated after tetracycline
three independent experiments. **P b .01; ***P b .005.
Figure 5. Suppression of p21 reduces ASPL-TFE3-induced senescence. (A) UE7T/TR-AT cells were transfected with either control siRNA
or p21 siRNAs (p21–1 and p21–2), and were then cultured in the presence of tetracycline (Tet +) for 48 h. Lysates of untreated UE7T/
TR-AT cells (−) or siRNA-transfected cells were subjected to immunoblotting using the indicated antibodies. (B) SA-β-gal staining was
performed in untreated UE7T/TR-AT cells (−) or UE7T/TR-AT cells transfected with either control siRNA or p21 siRNAs (p21–1 and p21–2)
after tetracycline treatment for 48 h. (C) Proportions of SA-β-gal-positive cells were calculated for all treatment groups. Data are presented
as mean ± SD of three independent experiments. *P b .05; ***P b .005.
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Despite the tumor-suppressing role of senescence-associated cell cycle
arrest, SASP has been suggested to promote tumorigenesis [36]. Thus,
we examined the expression of representative SASP-associated
proinflammatory cytokines, including IL1A, IL1B, IL6, and IL8, in
tetracycline-treated UE7T/TR-AT cells by quantitative real-timeFigure 6. ASPL-TFE3 up-regulates the expression of proinflamma-
tory cytokines. UE7T-TR-AT cells were cultured in the presence of
tetracycline for the indicated days, and then the expression of IL1A,
IL1B, IL6, and IL8 was analyzed by real-time quantitative PCR. Gene
expression data were normalized to those for beta-actin. Data are
presented as fold changes in mRNA levels relative to those on day
0 from three independent experiments. Error bars show SD;
*P b .05; **P b .01.PCR (Figure 6). At 4 days after tetracycline treatment, the expression
of IL1A, IL1B, and IL8 was significantly increased compared with
that of untreated UE7T/TR-AT cells. In contrast, the expression
levels of IL1B, IL6, and IL8 were decreased at 1 day after tetracycline
treatment, suggesting that the up-regulation of proinflammatory
cytokines is probably not due to direct transcriptional up-regulation
by ASPL-TFE3.
Discussion
The presence of the translocation t(X;17)(p11;q25) in almost all
ASPS cases suggests that the ASPL-TFE3 fusion gene contributes to
tumor formation and progression, but the corresponding oncogenic
mechanisms are poorly defined. Here, we demonstrate a novel
mechanism by which ASPL-TFE3 regulates cell cycle progression and
induces cellular senescence by directly up-regulating p21 expression. In
addition, we find that ASPL-TFE3 expression in MSCs induced the
expression of proinflammatory cytokines associated with the SASP.
Fusion oncogenes that act as transcription factors play critical roles
in tumor formation and progression through their transcriptional
targets. In this study, we identified p21 as a novel transcriptional
target of ASPL-TFE3. Ectopic expression of ASPL-TFE3 in 293 cells
resulted in growth arrest and increases in p21 protein and mRNA
levels. By luciferase and ChIP assays, we provided evidence that
ASPL-TFE3 directly interacts with the p21 promoter region and
activates it. Consistent with our results, another TFE3 fusion
oncoprotein, PRCCTFE3, which carries the DNA binding domain of
TFE3, causes cell cycle delays by transcriptionally up-regulating p21
expression [37]. Thus, TFE3 fusion oncoproteins appear to affect the
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be noted, however, that in clinical samples of Xp11 translocation
renal cell carcinomas, p21 protein overexpression has not been observed
consistently [38].
In this study, we show for the first time that ASPL-TFE3
expression can provoke cellular senescence. The expression of
activated oncogenes, such as Ras and fusion oncogenes, induces
OIS through activation of the p53/p21 pathway and/or p16 pathway
[27,28]. Our data revealed that ASPL-TFE3 expression in MSCs
induced some hallmarks of OIS, including the induction of SA-β-gal
activity and increased p21 expression. The expression of ASPL-TFE3
in MSCs increased the protein level of p21 while not affecting the
expression of p16, p53, and p27, suggesting that p21 is an important
mediator of ASPL-TFE3-induced senescence. Given that ASPL-TFE3
activated the p21 promoter in p53-deficient Kato III cells, ASPL-TFE3
appears to induce senescence in a p53-independent manner.
The significance of p21 in ASPL-TFE3-induced senescence was
further supported by the observation that the proportion of
SA-β-gal-positive cells was decreased after p21 suppression in
ASPL-TFE3-expressing UE7T/TR-AT cells. Nevertheless, p21 sup-
pression did not completely abolish the induction of SA-β-gal expression.
Recent studies suggest that OIS is mediated by sequential activation of
the p38 MAPK and PI3K/AKT/mTOR pathways [39–41]. Because
ASPL-TFE3 activates the MAPK pathway and PI3K/AKT/mTOR
pathway by directly up-regulating MET expression [18], additional
pathways that include the MAPK and PI3K/AKT/mTOR pathways
may also contribute to the ASPL-TFE3-induced senescence.
Our data demonstrate that ASPL-TFE3 expression in MSCs
induced cellular senescence, while ASPL-TFE3 expression in 293 cells
resulted in growth arrest but failed to induce senescence. These results
suggest that the cellular context is important for the molecular roles of
ASPL-TFE3. This notion is further supported by evidence that
despite harboring the same fusion gene, ASPS is cathepsin K positive,
while ASPL-TFE3-positive renal cell carcinoma is cathepsin K
negative [42]. The cellular origin of ASPS is currently unclear.
However, Goodwin et al. reported that ASPL-TFE3 expression alone,
without an additional oncogenic event, is sufficient for invasive
sarcomagenesis in mice [43]. Thus, the expression of ASPL-TFE3 in
an appropriate cell type may provide clues to understanding the
cellular events in ASPS pathogenesis. On the other hand, recent
studies have reported that the expression of sarcoma-associated fusion
genes, such as EWS-Fli1 and FUS-CHOP, in human MSCs resulted
in cellular transformation, implying that MSCs can provide a cellular
environment that enables sarcoma-specific fusion proteins to exert
their oncogenic potentials [32,44,45]. Gene expression profiling
studies of ASPS suggest that ASPSs express genes implicated in
myogenic, neurogenic, and stem cell differentiation, further supporting
the notion that mesenchymal stem/progenitor cells are appropriate for
use as a model for studying the biology of ASPS [46,47]. The issue of
whether ASPL-TFE3 can transform human MSCs remains to be
clarified, but ASPL-TFE3-expressing MSCs are thought to be a good
model for analyzing the cellular events in ASPL-TFE3-associated
sarcomagenesis.
Cellular senescence is a tumor-suppressive mechanism that
prevents uncontrolled proliferation [48–51]. However, accumulating
evidence suggests that senescent cells paradoxically promote tumor
progression through the SASP, which can affect their microenviron-
ment via the secretion of proinflammatory cytokines and growth
factors [52–54]. Our data revealed that ASPL-TFE3-inducedsenescence in MSCs was accompanied by an increase in the
expression of SASP-associated proinflammatory cytokines. SASP
factors have been shown to promote tumor progression by inducing
proliferation, epithelial-to-mesenchymal transformation (EMT), and
invasion, and promoting angiogenesis [55–57]. Although the exact
biological effect of this phenomenon on tumor cell behavior requires
further investigation, these observations raise the possibility that
ASPL-TFE3-induced senescence can alter the tissue microenviron-
ment by inducing SASP, which can promote malignant phenotypes
such as proliferation and invasiveness.
In conclusion, we demonstrate that p21 is a novel transcriptional
target of ASPL-TFE3 oncoprotein, and that ASPL-TFE3 affects cell
cycle machinery and induces cellular senescence by up-regulating p21
expression. Furthermore, the present work provides a potential
mechanism by which ASPL-TFE3-induced senescent cells may
promote a protumorigenic microenvironment by secreting proin-
flammatory cytokines. Since senescence plays an important role in
tumor prevention and influences the outcome of cancer therapy [58],
knowledge of the molecular mechanisms of ASPL-TFE3-induced
senescence may provide clues not only for understanding the
oncogenic properties of ASPL-TFE3 but also for developing future
therapeutic approaches for ASPS.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.08.001.
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